- Home
- ATOS vs CODA Comparison
ATOS vs CODA Comparison
Compare ATOS & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- CODA
- Stock Information
- Founded
- ATOS 2009
- CODA 1994
- Country
- ATOS United States
- CODA United States
- Employees
- ATOS N/A
- CODA N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- CODA Industrial Machinery/Components
- Sector
- ATOS Health Care
- CODA Industrials
- Exchange
- ATOS Nasdaq
- CODA Nasdaq
- Market Cap
- ATOS 106.9M
- CODA 88.8M
- IPO Year
- ATOS 2012
- CODA N/A
- Fundamental
- Price
- ATOS $0.77
- CODA $8.10
- Analyst Decision
- ATOS Strong Buy
- CODA
- Analyst Count
- ATOS 3
- CODA 0
- Target Price
- ATOS $6.25
- CODA N/A
- AVG Volume (30 Days)
- ATOS 539.9K
- CODA 73.2K
- Earning Date
- ATOS 11-12-2025
- CODA 09-15-2025
- Dividend Yield
- ATOS N/A
- CODA N/A
- EPS Growth
- ATOS N/A
- CODA 15.09
- EPS
- ATOS N/A
- CODA 0.30
- Revenue
- ATOS N/A
- CODA $24,347,217.00
- Revenue This Year
- ATOS N/A
- CODA $30.82
- Revenue Next Year
- ATOS N/A
- CODA $20.84
- P/E Ratio
- ATOS N/A
- CODA $27.10
- Revenue Growth
- ATOS N/A
- CODA 29.34
- 52 Week Low
- ATOS $0.55
- CODA $5.76
- 52 Week High
- ATOS $1.36
- CODA $10.54
- Technical
- Relative Strength Index (RSI)
- ATOS 34.80
- CODA 42.65
- Support Level
- ATOS $0.77
- CODA $7.80
- Resistance Level
- ATOS $0.85
- CODA $8.39
- Average True Range (ATR)
- ATOS 0.05
- CODA 0.44
- MACD
- ATOS -0.01
- CODA -0.13
- Stochastic Oscillator
- ATOS 18.62
- CODA 27.43
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About CODA Coda Octopus Group Inc. Common stock
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.